ALT - A Better Way To Crash The GLP-1 Party
2024-05-30 16:10:00 ET
Summary
- The global market for GLP-1 therapies now looks on pace to top $100 billion.
- GLP-1 pioneers such as Eli Lilly, Novo Nordisk, could be joined by new players Amgen, Altimmune, Pfizer, Viking, Roche, and privately held Boehringer Ingelheim that have GLP-1 based agents moving forward in clinical trials.
- We see potentially attractive opportunities among life sciences and tools companies that supply the drugmakers.
By Terri Towers
How to get an edge in the $100 bn global market for GLP-1-based weight loss therapies? Address their unwanted side effects. ...
A Better Way To Crash The GLP-1 Party